Literature DB >> 15921677

Hypericin in the dark inhibits key steps of angiogenesis in vitro.

Beatriz Martínez-Poveda1, Ana R Quesada, Miguel Angel Medina.   

Abstract

Photoactivated hypericin has a potent cytotoxic effect over a wide range of cells. However, very recently hypericin has been shown to have antitumoral and antimetastatic effects in the dark. The aim of this study was to test whether hypericin in the dark affects angiogenesis. Different in vitro assays were used to study the potential effects of this compound on key steps of angiogenesis, namely, a colorimetric assay of cell proliferation/viability, a tubular formation on Matrigel assay, zymographic assays for gelatinases and urokinase, a wound assay for migration and a fluorometric assay for invasion through Matrigel. In this report, we show for the first time that hypericin kept in the dark inhibits several key steps of the angiogenic process, namely, bovine endothelial cell proliferation, formation of tubular-like structures on Matrigel, migration and invasion, as well as extracellular matrix degrading urokinase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921677     DOI: 10.1016/j.ejphar.2005.03.047

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Photosensitizing effects of hypericin on head neck squamous cell carcinoma in vitro.

Authors:  Wiebke Laffers; Ann-Christin Busse; Jens Mahrt; Phuc Nguyen; Andreas O H Gerstner; Friedrich Bootz; Johannes T Wessels
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-01       Impact factor: 2.503

Review 2.  Hypericins as potential leads for new therapeutics.

Authors:  Anastasia Karioti; Anna Rita Bilia
Journal:  Int J Mol Sci       Date:  2010-02-04       Impact factor: 5.923

3.  Cyclic chalcone analogue KRP6 as a potent modulator of cell proliferation: an in vitro study in HUVECs.

Authors:  Lenka Ivanova; Lenka Varinska; Martina Pilatova; Peter Gal; Peter Solar; Pal Perjesi; Karel Smetana; Alexander Ostro; Jan Mojzis
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

4.  Epigallocatechin gallate reduces human monocyte mobility and adhesion in vitro.

Authors:  Esther Melgarejo; Miguel Angel Medina; Francisca Sánchez-Jiménez; José Luis Urdiales
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

5.  Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene.

Authors:  Casimiro Cárdenas; Ana R Quesada; Miguel A Medina
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

6.  Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases.

Authors:  M Barathan; V Mariappan; E M Shankar; B J J Abdullah; K L Goh; J Vadivelu
Journal:  Cell Death Dis       Date:  2013-06-27       Impact factor: 8.469

7.  The marine fungal metabolite, AD0157, inhibits angiogenesis by targeting the Akt signaling pathway.

Authors:  Melissa García-Caballero; Librada Cañedo; Antonio Fernández-Medarde; Miguel Ángel Medina; Ana R Quesada
Journal:  Mar Drugs       Date:  2014-01-16       Impact factor: 5.118

8.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

9.  Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy.

Authors:  Akiko Higuchi; Haruhiko Yamada; Eri Yamada; Nobuo Jo; Miyo Matsumura
Journal:  Mol Vis       Date:  2008-02-04       Impact factor: 2.367

Review 10.  Neuroprotective Activity of Hypericum perforatum and Its Major Components.

Authors:  Ana I Oliveira; Cláudia Pinho; Bruno Sarmento; Alberto C P Dias
Journal:  Front Plant Sci       Date:  2016-07-11       Impact factor: 5.753

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.